ClinicalTrials.gg
WithdrawnNCT02378636Updated Nov 22, 2023

Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens

An interventional study of 600S in Cataract, sponsored by Rayner Intraocular Lenses Limited. Withdrawn at 1 site in United Kingdom. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Rayner Intraocular Lenses Limited · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Study was never initiated
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This will be a prospective, open-label, 125 subject (maximum), two-year multicentre investigation to assess the safety, effectiveness and rotational stability of the modified 600C (axis marks) intraocular lens (IOL) in subjects undergoing cataract extraction.

02

Conditions studied

  • Cataract

Browse trials for

03

In context

Cataract

1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Lead sponsor

Rayner Intraocular Lenses Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥21 years of age.
  • Cataract for which phacoemulsification extraction and posterior IOL implantation has been planned for the operative eye.
  • Best corrected distance visual acuity (BCDVA) projected to be better than 20/30 (+0.18 logMAR) in the operative eye after cataract removal and IOL implantation.
  • Calculated IOL power requirement within the range +8.0 to +34.0D
  • If present, subject must have corneal astigmatism of \<1.50 D in the operative eye.
  • Expected dilated pupil size ≥ 5.0 mm in diameter to visualise the axis markings
  • Subject must provide written .
  • Subject must be able to return for scheduled follow-up examinations for 24 months after surgery.

Exclusion criteria

Exclusion Criteria:

  • History of ocular trauma or prior ocular surgery in the operative eye.
  • Microphthalmia
  • Corneal decompensation or endothelial insufficiency
  • Pseudo exfoliation
  • Pars planitis
  • Subjects with diagnosed degenerative visual disorders in the operative eye (e.g.,macular degeneration or other retinal disorders) that are predicted to cause future visual acuity losses to a level of 20/30 (+0.18 logMAR) or worse.
  • Inability to achieve secure placement in the designated location e.g. absence of a secure peripheral anterior capsule, zonule laxity or dehiscence; posterior synechiae to the capsular bag
  • Active ocular disease in the operative eye, e.g., dystrophy, chronic severe uveitis, proliferative diabetic retinopathy, or chronic glaucoma.
  • Concurrent participation in another drug or device investigation.
  • Patients who are expected to require retinal laser treatment.
  • Females who are pregnant, nursing or plan to become pregnant during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    600S

    Modified 600C (axis marks) monofocal aspheric intraocular lens

    Device: 600S

Interventions

  • Device600S

    Monofocal Aspheric Intraocular Lens (IOL)

    Also known as: Modified 600C (axis marks)

06

What researchers measure

Primary outcomes

  1. Best Corrected Distance Visual Acuity (BCDVA)

    Best Corrected Distance Visual Acuity

    Time frame: 180 Day

  2. Rotational Stability

    IOL rotation will be measured through retro-illumination photography between 0-3 hours post-operatively and this will be compared with images from Day 120-180 to determine degree of IOL rotation in accordance with ISO-11979-7:2014 requirements

    Time frame: 180 Day

07

Study locations

1 site
  • Contact Rayner Intraocular Lenses Limited for Locations
    Hove, East Sussex BN3 7AN, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02378636
Lead sponsor
Rayner Intraocular Lenses Limited
Collaborators
Visioncare Research Ltd.
Responsible party
Sponsor
First posted
Mar 4, 2015
Start date
Jun 2015
Primary completion
Jan 2016 (estimated)
Completion
Aug 2017 (estimated)
Last update
Nov 22, 2023

Study contacts

Mark Packer, MD
study chair · Consultant

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion